Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-03-15 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于回购注销激励对象已获授但尚未解锁的限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from 哈药集团股份有限公司 regarding the repurchase and cancellation of restricted shares granted but not yet unlocked under a stock incentive plan. It includes specifics about the stock incentive plan, board and supervisory approvals, independent director opinions, legal opinions, repurchase prices, quantities, and the impact on share capital structure. The document is not a full financial report, earnings release, or annual report, but rather a formal announcement about a share repurchase related to incentive stock plans. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares. The document length is 4577 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is POS with high confidence.
2019-03-15 Chinese
独立董事关于对限制性股票回购事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent opinion from the independent directors of Harbin Pharmaceutical Group Co., Ltd. regarding the repurchase of restricted shares. It discusses the legality and compliance of the stock repurchase under relevant laws and company regulations. The content is a formal opinion on a specific corporate action (restricted stock repurchase) rather than a full financial report, earnings release, or management discussion. It is not a general regulatory filing or announcement of voting results. The document is short (459 characters) and focused on the stock repurchase matter, which aligns with the category of Transaction in Own Shares (POS), as it reports on the company's buyback of its own shares (restricted stock).
2019-03-15 Chinese
关于回购注销限制性股票通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding the repurchase and cancellation of restricted shares, including details about notifying creditors and the reduction of registered capital. It includes procedural information for creditors to declare claims within specified periods. The content focuses on a capital change event (share repurchase and cancellation) and related creditor notification, not a financial report or earnings release. The document length is short (1121 characters), and it is an official announcement about share repurchase and capital reduction, fitting the category of Transaction in Own Shares (POS).
2019-03-15 Chinese
董事会审计委员会2018年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2018 Annual Performance Report" of Harbin Pharmaceutical Group Co., Ltd. It details the audit committee's composition, meetings held in 2018, their oversight of external and internal audits, review of financial reports, and evaluation of internal controls. The content focuses on the audit committee's activities and their report to the board for the year 2018. It is not a full annual report (10-K), nor a standalone audit report by auditors, but rather a committee's report on their audit-related duties and findings. This fits the category of Audit Report / Information (AR), which includes reports on audit committee activities and audit results separate from the full annual report. The document length is 2429 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2018
2019-03-15 Chinese
八届十七次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details the decisions made at the 17th meeting of the 8th board, including approval of the 2018 annual report, board work report, independent directors' report, audit committee report, audit firm reappointment, financial budget, internal control reports, asset impairment provisions, profit distribution plan, bank credit applications, amendments to the company charter, related party transactions, and share repurchase plans. The document repeatedly references that the full reports and details are disclosed separately on the Shanghai Stock Exchange website, indicating this document itself is a summary announcement of board decisions rather than the full reports. The document length is 2658 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on board meeting resolutions and approvals, which aligns with the category of Board/Management Information (MANG). Therefore, the document is best classified as MANG.
2019-03-15 Chinese
2018年年度报告
Annual Report Classification · 100% confidence The document is titled "2018 年年度报告" which translates to "2018 Annual Report". It contains detailed financial data, including income statements, cash flow statements, profit distribution plans, risk disclosures, business overview, management discussion and analysis, and other comprehensive information typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial statements with an unqualified audit opinion from Beijing Xinghua Accounting Firm, detailed segment financials, and extensive narrative on business operations and strategy. These characteristics align with the definition of an Annual Report (10-K). FY 2018
2019-03-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.